Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: Presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection

被引:40
作者
Stewart, M. [1 ]
Dovas, C. I. [2 ]
Chatzinasiou, E. [2 ]
Athmaram, T. N. [1 ]
Papanastassopoulou, M. [2 ]
Papadopoulos, O. [2 ]
Roy, P. [1 ]
机构
[1] Univ London London Sch Hyg & Trop Med, Dept Infect Dis, London WC1E 7HT, England
[2] Aristotle Univ Thessaloniki, Lab Microbiol & Infect Dis, Fac Vet Med, Thessaloniki 54124, Greece
关键词
Vaccine; Bluetongue Virus; VLPs; Lineage; OUTER CAPSID PROTEINS; VACCINE; EXPRESSION; NEUTRALIZATION; RESPONSES; GENES; IDENTIFICATION; BTV;
D O I
10.1016/j.vaccine.2012.01.042
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There have been multiple separate outbreaks of Bluetongue (BT) disease of ruminants in Europe since 1998, often entering via the Mediterranean countries of Italy. Spain and Greece. BT is caused by an orbivirus, Bluetongue virus (BTV), a member of the family Reoviridae. BTV is a non-enveloped double-capsid virus, which encodes 7 structural proteins (VP1-VP7) and several non-structural proteins (NS1, NS2, NS3/3a and NS4) from ten double-stranded RNA segments of the genome. In this report, we have prepared BTV virus-like particles (VLPs, composed of VP2, VP3, VP5 and VP7) and sub-viral, inner core-like particles (CLPs, VP3 and VP7) using a recombinant baculovirus expression system. We compared the protective efficacy of VLPs and CLPs in sheep and investigated the importance of geographical lineages of BTV in the development of vaccines. The Greek crossbred Karagouniko sheep, which display mild to sub-clinical BT, were vaccinated with VLPs or CLPs of BTV-1, derived from western lineage and were challenged with virulent BTV-1 from an eastern lineage. All VLP-vaccinated animals developed a neutralising antibody response to BTV-1 from both lineages prior to challenge. Moreover, post-challenged animals had no clinical manifestation or viraemia and the challenged virus replication was completely inhibited. In contrast, CLP-vaccinated animals did not induce any neutralising antibody response but developed the group specific VP7 antibodies. CLPs also failed to prevent the clinical manifestation and virus replication, but in comparison to controls, the severity of disease manifestation and viraemia was mitigated. The data demonstrated that the outer capsid was essential for complete protection, while the geographical origin of the BTV was not critical for development of a serotype specific vaccine. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2131 / 2139
页数:9
相关论文
共 42 条
[1]   A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment [J].
Batten, Carrie A. ;
Maan, Sushila ;
Shaw, Andrew E. ;
Maan, Narender S. ;
Mertens, Peter P. C. .
VIRUS RESEARCH, 2008, 137 (01) :56-63
[2]   DEVELOPMENT OF BACULOVIRUS TRIPLE AND QUADRUPLE EXPRESSION VECTORS - COEXPRESSION OF 3 OR 4 BLUETONGUE VIRUS PROTEINS AND THE SYNTHESIS OF BLUETONGUE VIRUS-LIKE PARTICLES IN INSECT CELLS [J].
BELYAEV, AS ;
ROY, P .
NUCLEIC ACIDS RESEARCH, 1993, 21 (05) :1219-1223
[3]   Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep [J].
Boone, Josh D. ;
Balasuriya, Udeni B. ;
Karaca, Kemal ;
Audonnet, Jean-Christophe ;
Yao, Jiansheng ;
He, Ling ;
Nordgren, Robert ;
Monaco, Federica ;
Savini, Giovanni ;
Gardner, Ian A. ;
MacLachlan, N. James .
VACCINE, 2007, 25 (04) :672-678
[4]   Recovery of infectious bluetongue virus from RNA [J].
Boyce, Mark ;
Roy, Polly .
JOURNAL OF VIROLOGY, 2007, 81 (05) :2179-2186
[5]   Comparison of genome segments 2, 7 and 10 of bluetongue viruses serotype 2 for differentiation between field isolates and the vaccine strain [J].
Bréard, E ;
Sailleau, C ;
Coupier, H ;
Mure-Ravaud, K ;
Hammoumi, S ;
Gicquel, B ;
Hamblin, C ;
Dubourget, P ;
Zientara, S .
VETERINARY RESEARCH, 2003, 34 (06) :777-789
[6]   Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection [J].
Calvo-Pinilla, Eva ;
Rodriguez-Calvo, Teresa ;
Sevilla, Noemi ;
Ortego, Javier .
VACCINE, 2009, 28 (02) :437-445
[7]   Assessment of bluetongue viraemia in sheep by real-time PCR and correlation with viral infectivity [J].
Chatzinasiou, E. ;
Dovas, C. I. ;
Papanastassopoulou, M. ;
Georgiadis, M. ;
Psychas, V. ;
Bouzalas, I. ;
Koumbati, M. ;
Koptopoulos, G. ;
Papadopoulos, O. .
JOURNAL OF VIROLOGICAL METHODS, 2010, 169 (02) :305-315
[8]   Isolation and identification of bluetongue virus [J].
Clavijo, A ;
Heckert, RA ;
Dulac, GC ;
Afshar, A .
JOURNAL OF VIROLOGICAL METHODS, 2000, 87 (1-2) :13-23
[9]   Characterization of Protection Afforded by a Bivalent Virus-Like Particle Vaccine against Bluetongue Virus Serotypes 1 and 4 in Sheep [J].
Cristina Perez de Diego, Ana ;
Athmaram, Thimmasandra N. ;
Stewart, Meredith ;
Rodriguez-Sanchez, Belen ;
Manuel Sanchez-Vizcaino, Jose ;
Noad, Robert ;
Roy, Polly .
PLOS ONE, 2011, 6 (10)
[10]   NEUTRALIZATION DETERMINANTS OF UNITED-STATES BLUETONGUE VIRUS SEROTYPE-10 [J].
DEMAULA, CD ;
HEIDNER, HW ;
ROSSITTO, PV ;
PIERCE, CM ;
MACLACHLAN, NJ .
VIROLOGY, 1993, 195 (01) :292-296